Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955084 · ClinicalTrials.gov registry record · Phase 1
Maintenance Study on the Long Term Safety of XL999
A Phase 1 study of Advanced Malignancies, sponsored by Symphony Evolution.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 2
- Study locations
NCT00955084: Completed Phase 1 study of Advanced Malignancies, sponsored by Symphony Evolution.
NCT00955084 is a Phase 1 study of Advanced Malignancies that has completed, run by Symphony Evolution. The registered enrollment target is 2 participants, below the 89-participant average among 10 other Advanced Malignancies trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00955084, a Phase 1 study of Advanced Malignancies, has completed, sponsored by Symphony Evolution.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this study is to allow rollover of the two remaining subjects from the other XL999 studies to continue to receive XL999. The secondary objectives of this study are as follows: * To evaluate tumor response after long term repeat administration of XL999 in two subjects rolled over from other XL999 studies. * To characterize the long term safety and tolerability of XL999 after repeat administration in two subjects rolled over from other XL999 studies. * To characterize the long term effects of XL999 on cardiac function after repeat administration in two subjects rolled over from other XL999 studies.
Conditions Studied
Interventions
- DRUG XL999
Study Locations (2)
New York
- Hematology Oncology Associates of Rockland Union State Bank Cancer Center - Nyack
Texas
- University of Texas Cancer Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
What the finished NCT00955084 record still lists
NCT00955084 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 89-participant average among 10 other Advanced Malignancies trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Advanced Malignancies appearing as the primary indexed condition, and to 1 intervention - of which XL999 is the first listed.
NCT00955084 reports a single indexed study location in New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00955084 about?
NCT00955084 is a clinical study titled "Maintenance Study on the Long Term Safety of XL999". The primary objective of this study is to allow rollover of the two remaining subjects from the other XL999 studies to continue to receive XL999. The secondary objectives of this study are as follows: * To evaluate tumor response after long term repeat administration of XL999 in two subjects rolle...
What is the current status of trial NCT00955084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2008-08. Estimated completion is 2010-05.
What conditions does trial NCT00955084 study?
This clinical trial studies the following conditions: Advanced Malignancies.
What interventions are being tested in trial NCT00955084?
The interventions under investigation include: XL999 (DRUG).
Who is sponsoring clinical trial NCT00955084?
This trial is sponsored by Symphony Evolution, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00955084 being conducted?
This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00955084's enrollment target sits among peer trials
2 11th of 10 the lowest of 10 other Advanced Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
-
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
COMPLETED · Phase 1
-
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
COMPLETED · Phase 1
-
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
COMPLETED · Phase 1
-
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia